Meta AnalysisID 6569
血脂康胶囊对冠心病合并高脂血症患者的降脂作用：系统评价方案
CRD42017062486
The curative effect of XZK in patients with CHD combined with hyperlipidemia
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6569
- Evidence Id
- 15127
- Core Evidence Id
- 15127
- Source Meta Analysis Id
- 6551
- Herb2 Meta Analysis Id
- HBMA006551
- Crd Id
- CRD42017062486
- Title
- Lipid-lowering effect of Xuezhikang capsule for patients with coronary heart disease combined with hyperlipidemia: protocol for a systematic review
- Review Question
- The curative effect of XZK in patients with CHD combined with hyperlipidemia
- Study Type Included
- Randomized controlled trials (RCTs)
- Condition Being Studied
- Dyslipidemia is a risk for cardiovascular disease. Statins can cut down the level of TC and LDL-C but also bring adverse reactions such as giving rise to transaminase elevation, rhabdomyolysis, and so on. Xuezhikang (XZK) capsule has been widely used for dyslipidemia as a treatment in China. Many clinical trials have been reported that it could lower the blood lipid level.
- Participant
- Patients with both Coronary heart disease (CHD) and hyperlipidemia will be included. Patients with CHD and hyperlipidemia will be included regardless of their age, sex, ethnicity/race, education or economic status. Familial hypercholesterolemia, Secondary hyperlipidemia, Postprandial hyperlipidemia and serious liver and kidney diseases will be excluded.
- Animal
- Human Disease Modelled
- Intervention
- For the treatment group, XZK interventions will be adopted, which combine with conventional therapy. Trials include any other Chinese medicine interventions (e.g. decoction of Chinese medicine, acupuncture and etc.) will be excluded.
- Comparator Control
- XZK Interventions will not be adopted of the control group, treating in conventional therapy (basic glucose-lowering drugs) plus placebos or statins or no other drugs.
- Main Outcome
- Total cholesterol (TC), triglyceride(TG), high density lipoprotein cholesterol(HDL-C), and low density lipoprotein cholesterol (LDL-C)
- Outcome Measure
- Additional Outcome
- Adverse event.
- Study Method
- Systematic review
- Keyword
- Coronary Artery Disease; Drugs, Chinese Herbal; Humans; Hyperlipidemias; Lipids
- Contact
- Professor Wu [email protected]
- Organisational Affiliation
- The first affiliated hospital of Guangzhou university of Chinese medicine http://www.gztcm.com.cn/
- Funding Source
- This project was supported by BEIJING WBL PEKING UNIVERSITY BIOTECH CO., LTD and the State Administration of Traditional Medicine of China (grant no. 2015 LP01).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2017-04-20
- Anticipated Start Date
- 2017-05-31
- Anticipated Completion Date
- 2017-06-30
- Title Cn
- 血脂康胶囊对冠心病合并高脂血症患者的降脂作用：系统评价方案
- Title En
- Lipid-lowering effect of Xuezhikang capsule for patients with coronary heart disease combined with hyperlipidemia: protocol for a systematic review
- Bilingual Status
- complete